Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330382 · ClinicalTrials.gov registry record · Phase 2
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 325
- Enrollment target
NCT00330382: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00330382 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 325 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00330382, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 325 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well Bowman-Birk inhibitor concentrate works in preventing cancer in patients with oral leukoplakia. Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. The use of Bowman-Birk inhibitor concentrate, a substance made from soy, may keep cancer from forming in patients with oral leukoplakia
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- DRUG Bowman-Birk inhibitor concentrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 1999-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330382
The ClinicalTrials.gov registry entry for NCT00330382 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00330382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00330382 about?
NCT00330382 is a clinical study titled "Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia". This randomized phase II trial is studying how well Bowman-Birk inhibitor concentrate works in preventing cancer in patients with oral leukoplakia. Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. The use of Bowman-Birk inhibitor concentrate, a s...
What is the current status of trial NCT00330382?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 325 participants. The study started on 1999-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00330382?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), Bowman-Birk inhibitor concentrate (DRUG).
Who is sponsoring clinical trial NCT00330382?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.